Comparative analysis on the anti-inflammatory/immune effect of mesenchymal stem cell therapy for the treatment of pulmonary arterial hypertension

Autor: Sehyun Chae, Roham T. Zamanian, Kyunghee Byun, Daehee Hwang, Minsu Kim, Seyeon Oh, Jeongsik Moon, Wook-Jin Chung, Edda Spiekerkoetter, Albert Youngwoo Jang, Seungbum Choi, Phillip C. Yang
Jazyk: angličtina
Rok vydání: 2021
Předmět:
0301 basic medicine
Pathology
medicine.medical_specialty
Cell biology
Molecular biology
Science
Cell- and Tissue-Based Therapy
Adipose tissue
Bone Marrow Cells
Stem cells
030204 cardiovascular system & hematology
Pulmonary Artery
Vascular Remodeling
Mesenchymal Stem Cell Transplantation
Umbilical cord
Article
Proinflammatory cytokine
03 medical and health sciences
0302 clinical medicine
Immune system
Medicine
Animals
Humans
Cell Proliferation
Pulmonary Arterial Hypertension
Multidisciplinary
business.industry
Mesenchymal stem cell
Therapeutic effect
Mesenchymal Stem Cells
medicine.disease
Pulmonary hypertension
Rats
Disease Models
Animal
030104 developmental biology
medicine.anatomical_structure
Gene Expression Regulation
Ventricular Function
Right
Bone marrow
Cord Blood Stem Cell Transplantation
business
Biotechnology
Zdroj: Scientific Reports, Vol 11, Iss 1, Pp 1-15 (2021)
Scientific Reports
ISSN: 2045-2322
Popis: Despite the advancement of targeted therapy for pulmonary arterial hypertension (PAH), poor prognosis remains a reality. Mesenchymal stem cells (MSCs) are one of the most clinically feasible alternative treatment options. We compared the treatment effects of adipose tissue (AD)-, bone marrow (BD)-, and umbilical cord blood (UCB)-derived MSCs in the rat monocrotaline-induced pulmonary hypertension (PH) model. The greatest improvement in the right ventricular function was observed in the UCB-MSCs treated group. The UCB-MSCs treated group also exhibited the greatest improvement in terms of the largest decrease in the medial wall thickness, perivascular fibrosis, and vascular cell proliferation, as well as the lowest levels of recruitment of innate and adaptive immune cells and associated inflammatory cytokines. Gene expression profiling of lung tissue confirmed that the UCB-MSCs treated group had the most notably attenuated immune and inflammatory profiles. Network analysis further revealed that the UCB-MSCs group had the greatest therapeutic effect in terms of the normalization of all three classical PAH pathways. The intravenous injection of the UCB-MSCs, compared with those of other MSCs, showed superior therapeutic effects in the PH model for the (1) right ventricular function, (2) vascular remodeling, (3) immune/inflammatory profiles, and (4) classical PAH pathways.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje